Artwork

Sisällön tarjoaa IMPACT Medicom. IMPACT Medicom tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

First Line la/mUC Evolving Treatment Strategies: S2 Ep 3 - Case Discussion

8:07
 
Jaa
 

Manage episode 379361762 series 2812899
Sisällön tarjoaa IMPACT Medicom. IMPACT Medicom tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.

This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.
In this third episode taken from the webinar, Dr. Srikala Sridhar presents a clinical case on the treatment of locally advanced metastatic urothelial carcinoma, highlighting the role of enfortumab vedotin plus pembrolizumab in the treatment plan.
Our Guests:
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
This podcast episode was sponsored by Seagen Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

  continue reading

64 jaksoa

Artwork
iconJaa
 
Manage episode 379361762 series 2812899
Sisällön tarjoaa IMPACT Medicom. IMPACT Medicom tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.

This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.
In this third episode taken from the webinar, Dr. Srikala Sridhar presents a clinical case on the treatment of locally advanced metastatic urothelial carcinoma, highlighting the role of enfortumab vedotin plus pembrolizumab in the treatment plan.
Our Guests:
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
This podcast episode was sponsored by Seagen Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

  continue reading

64 jaksoa

Kaikki jaksot

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas